Topadur Pharma AG
17.12.2025 - 09:30:03Topadur Appoints Matthias Schäfer as Chief Executive Officer to Lead Next Phase of Company Growth
| Topadur Pharma AG / Key word(s): Personnel 17.12.2025 / 09:30 CET/CEST The issuer is solely responsible for the content of this announcement. 17 December 2025 Founder and President of the Board Dr. Reto Naef assumes the role of Senior Scientific Advisor, continuing to support the company’s scientific direction Company enters next phase of clinical advancement with programs progressing toward strategic milestones Zurich, Switzerland - Topadur Pharma AG, a clinical-stage biotechnology company developing innovative therapies for vascular regeneration, today announced the appointment of PD Dr. Matthias Schäfer as Chief Executive Officer. Dr. Schäfer joined Topadur in 2024 as Chief Innovation Officer and Deputy CEO and now assumes executive leadership as the company advances its pipeline into the next stages of clinical development toward commercialization. Founder Dr. Reto Naef remains on the leadership team as Senior Scientific Advisor and continues to guide the company’s strategy as President of the Board, ensuring continuity in Topadur’s long-term growth. Matthias Schäfer brings more than 20 years of experience across the life sciences and healthcare sectors. He has directed research and clinical development programs, driven global portfolio expansion, and established strategic partnerships across diverse therapeutic areas. Dr. Schäfer has held senior leadership roles including at Geistlich Pharma AG and pfm medical GmbH, where he translated scientific innovation into sustainable commercial growth and strengthened global market presence. He received a PhD in Biology from the University of Würzburg and completed his habilitation at ETH Zurich. “Topadur is entering an important phase as we advance toward meaningful clinical milestones,” said Dr. Schäfer. “Our priorities are progressing our lead programs in the clinical phases, increasing liquidity, and strengthening the organizational capabilities and partnerships needed to support continued growth. I look forward to working closely with our outstanding team to build on this momentum and advance our programs through their upcoming inflection points.” “As a scientist and entrepreneur, I founded Topadur with the conviction that vascular regeneration has the power to treat a variety of aging-related diseases,” said Dr. Naef. “Today, the company stands on a strong scientific and clinical foundation. With Matthias stepping into the CEO role, we are ready to accelerate momentum and advance our programs into the next stage. I look forward to continuing to help shape Topadur’s strategic and scientific direction as President of the Board and in my new role as Senior Scientific Advisor.” Advancing the Technology Platform and Clinical Pipeline Topadur’s DualTOP® platform is designed to restore healthy microcirculation and support tissue regeneration across multiple therapeutic areas. The company’s lead asset, TOP-N53, is in Phase 2a clinical development for treatment of digital ulcers in patients with systemic sclerosis and has received Orphan Drug Designation from both the FDA and EMA. Supported by positive clinical Phase 1 data, TOP-N53 is also being advanced for development in diabetic foot ulcers, a major global health challenge and area of significant unmet clinical need, with one diabetes-related amputation occurring every 20 seconds[i]. Topadur’s second lead asset, TOP-M119, targeting androgenetic and chemotherapy-induced alopecia, is completing toxicology studies ahead of planned clinical entry. Building on the regenerative potential of the DualTOP® platform, Topadur is also prioritizing innovative applications in skin rejuvenation and longevity, areas with rapidly growing scientific and commercial relevance. Complementary exploratory investigations are underway in oncology and other indications. About Topadur Topadur Pharma AG is a Swiss clinical-stage biotechnology company developing first-in-class therapies that restore microvascular function and reactivate tissue regeneration. Founded in 2015, the company focuses on diseases where impaired local blood flow is a key driver of tissue degeneration, impaired repair processes, and progression of chronic conditions with aging. Topadur’s proprietary DualTOP® platform targets the signaling cascade of cGMP, a central regulator of blood vessel function and tissue repair, through a dual mechanism designed to improve microcirculation directly at the site of disease. The company is advancing a pipeline of first-in-class candidates in high-need indications, supported by a capital-efficient, partnership-driven R&D model and a global network of scientific collaborators. Beyond these lead indications, Topadur is pursuing focused preclinical programs in conditions where improved microcirculation may offer therapeutic benefit. For more information, please visit: www.topadur.com Contact Topadur Pharma AG Yoshita Bhide Media Communications +41 44 755 44 66 yoshita.bhide@topadur.com Disclaimer This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Topadur Pharma AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions. New England Journal of Medicine, 376(24):2367–2375. 17.12.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. View original content: EQS News |
